FUTURE 2 |
SEC 300 mg: SEC 300 mg SC once a week from baseline to week 4 and then every 4 weeks |
100 |
46.9±12.6 |
49 (49) |
No data |
85.4±18.4 |
Corticosteroids (≤10 mg/day PDN or equivalent) at a stable dose for ≥2 weeks; MTX ≤25 mg/week at a stable dose for ≥4 weeks; Anti-TNF-IR. |
8 |
McInnes et al. (1919. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137-46. https://doi.org/10.1016/S0140-6736(15)61134-5 https://doi.org/10.1016/S0140-6736(15)61...
) |
Lancet |
SEC 150 mg: SEC 150 mg SC once a week from baseline to week 4 and then every 4 weeks |
100 |
46.5±11.7 |
45 (45) |
No data |
91.2±19.8 |
Kavanaugh et al. (2020. Kavanaugh A, McInnes IB, Mease PJ, Hall S, Chinoy H, Kivitz AJ, et al. Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. J Rheumatol. 2016;43(9):1713-7. https://doi.org/10.3899/jrheum.160275 https://doi.org/10.3899/jrheum.160275...
) McInnes et al. (2121. McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017;56(11):1993-2003. https://doi.org/10.1093/rheumatology/kex301 https://doi.org/10.1093/rheumatology/kex...
) |
J Rheumatol Rheumatology |
FUTURE 3 |
SEC 300 mg: SEC 300 mg SC once a week from baseline to week 4 and then every 4 weeks |
139 |
49.3±12.9 |
72 (51.8) |
8.3±9.2 |
87.1±19.4 |
Corticosteroids (≤10 mg/day PDN or equivalent) at a stable dose for ≥2 weeks; MTX ≤25 mg/week at a stable dose for ≥4 weeks; Anti-TNF-IR. |
8 |
Nash et al. (2222. Nash P, Mease PJ, McInnes IB, Rahman P, Ritchlin CT, Blanco R, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018;20(1):47. https://doi.org/10.1186/s13075-018-1551-x https://doi.org/10.1186/s13075-018-1551-...
) |
Arthritis Research & Therapy |
SEC 150 mg: SEC 150 mg SC once a week from baseline to week 4 and then every 4 weeks |
138 |
50.1±11.7 |
77 (55.8) |
7.7±8.5 |
87.1±20.0 |
FUTURE 5 |
SEC 300 mg with LD: SEC 300 mg SC once a week from baseline to week 3 and then every 4 weeks |
222 |
48.9±12.8 |
114 (51.4) |
6.7±8.3 |
81.9±16.9 |
Corticosteroids(≤10 mg/day PDN or equivalent), NSAIDs and MTX (≤25 mg/week) at a stable dose for the first 24 weeks of the study; Anti-TNF-IR. |
8 |
Mease et al. (2323. Mease P, van der Heijde D, Landewé R, Mpofu S, Rahman P, Tahir H, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890-7. https://doi.org/10.1136/annrheumdis-2017-212687 https://doi.org/10.1136/annrheumdis-2017...
) |
Ann Rheum Dis |
SEC 150 mg with LD: SEC 150 mg SC once a week from baseline to week 3 and then every 4 weeks |
220 |
48.4±12.9 |
109 (49.5) |
6.7±7.1 |
83.3±19.6 |
van der Heijde et al. (2424. van der Heijde D, Mease PJ, Landewé RBM, Rahman P, Tahir H, Singhal A, et al. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology (Oxford). 2020;59(6):1325-34. https://doi.org/10.1093/rheumatology/kez420 https://doi.org/10.1093/rheumatology/kez...
) |
Rheumatology |
SEC 150 mg without LD: SEC 150 mg SC once a week from week 1 to week 3 and then every 4 weeks |
222 |
48.8±11.8 |
102 (45.9) |
6.2±6.1 |
84.1±20.5 |